About this document
Sunitinib Efficacy in Metastatic RCC by iancooke09 is a document available to read on EtoBox.
This document presents a clinical trial evaluating the efficacy of sunitinib, an oral multitargeted tyrosine kinase inhibitor, as a second-line treatment for patients with metastatic clear-cell renal cell carcinoma (RCC) who have previously failed cytokine therapy. The trial involved 106 patients and reported a 34% objective response rate with a median progression-free survival of 8.3 months, demonstrating sunitinib
- Author
- iancooke09
- Language
- EN